147 related articles for article (PubMed ID: 35674182)
1. Rosmarinic acid ameliorated psoriatic skin inflammation in mice through the novel inhibition of the interleukin-17A/interleukin-17A receptor interaction.
Ho TY; Lo HY; Liu IC; Huang SL; Hsiang CY
Food Funct; 2022 Jun; 13(12):6802-6812. PubMed ID: 35674182
[TBL] [Abstract][Full Text] [Related]
2. Ferulic acid altered IL-17A/IL-17RA interaction and protected against imiquimod-induced psoriasis-like skin injury in mice.
Lo HY; Li CC; Cheng HM; Liu IC; Ho TY; Hsiang CY
Food Chem Toxicol; 2019 Jul; 129():365-375. PubMed ID: 31054998
[TBL] [Abstract][Full Text] [Related]
3. 3, 3'- diindolylmethane hinders IL-17A/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice.
Srikanth M; Rasool M
Int Immunopharmacol; 2022 Aug; 109():108795. PubMed ID: 35487087
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
[TBL] [Abstract][Full Text] [Related]
5. Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.
Zhang M; Li N; Cai R; Gu J; Xie F; Wei H; Lu C; Wu D
Phytother Res; 2021 Aug; 35(8):4526-4537. PubMed ID: 34008239
[TBL] [Abstract][Full Text] [Related]
6. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.
El Malki K; Karbach SH; Huppert J; Zayoud M; Reissig S; Schüler R; Nikolaev A; Karram K; Münzel T; Kuhlmann CR; Luhmann HJ; von Stebut E; Wörtge S; Kurschus FC; Waisman A
J Invest Dermatol; 2013 Feb; 133(2):441-51. PubMed ID: 22951726
[TBL] [Abstract][Full Text] [Related]
7. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells.
Zheng QY; Xu F; Yang Y; Sun DD; Zhong Y; Wu S; Li GQ; Gao WW; Wang T; Xu GL; Liang SJ
FASEB J; 2020 Aug; 34(8):10590-10604. PubMed ID: 32557852
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes.
Moos S; Mohebiany AN; Waisman A; Kurschus FC
J Invest Dermatol; 2019 May; 139(5):1110-1117. PubMed ID: 30684554
[TBL] [Abstract][Full Text] [Related]
9. Asiatic acid exerts an anti-psoriatic effect in the imiquimod-induced psoriasis model in mice.
Kukula O; Kırmızıkan S; Tiryaki ES; Çiçekli MN; Günaydın C
Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):367-372. PubMed ID: 35253588
[No Abstract] [Full Text] [Related]
10. Discovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway.
Álvarez-Coiradas E; Munteanu CR; Díaz-Sáez L; Pazos A; Huber KVM; Loza MI; Domínguez E
Int Immunopharmacol; 2020 Dec; 89(Pt A):107026. PubMed ID: 33045560
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
[TBL] [Abstract][Full Text] [Related]
12. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
Ma L; Xue H; Qi R; Wang Y; Yuan L
J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
[TBL] [Abstract][Full Text] [Related]
13. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
[TBL] [Abstract][Full Text] [Related]
15. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model.
Al-Harbi NO; Nadeem A; Al-Harbi MM; Zoheir KMA; Ansari MA; El-Sherbeeny AM; Alanazi KM; Alotaibi MR; Ahmad SF
Immunobiology; 2017 Feb; 222(2):128-136. PubMed ID: 27773660
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Mitochondrial Translation Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation by Targeting Vγ4+ γδ T Cells.
Dhillon-LaBrooy A; Braband KL; Tantawy E; Rampoldi F; Kao YS; Boukhallouk F; Velasquez LN; Mamareli P; Silva L; Damasceno LEA; Weidenthaler-Barth B; Berod L; Almeida L; Sparwasser T
J Invest Dermatol; 2024 Apr; 144(4):844-854.e2. PubMed ID: 37832844
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation.
Su Y; Huang J; Zhao X; Lu H; Wang W; Yang XO; Shi Y; Wang X; Lai Y; Dong C
Sci Immunol; 2019 Jun; 4(36):. PubMed ID: 31175175
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
Nadeem A; Al-Harbi NO; Al-Harbi MM; El-Sherbeeny AM; Ahmad SF; Siddiqui N; Ansari MA; Zoheir KM; Attia SM; Al-Hosaini KA; Al-Sharary SD
Pharmacol Res; 2015 Sep; 99():248-57. PubMed ID: 26149470
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling and rational design of disulfide-stapled self-inhibitory peptides to target IL-17A/IL-17RA interaction.
Huang W; Zhou Y; Pan C; Zhang X; Zhao H; Shen L
J Mol Recognit; 2023 Aug; 36(8):e3045. PubMed ID: 37415317
[TBL] [Abstract][Full Text] [Related]
20. Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Shokrian Zeini M; Haddadi NS; Shayan M; Shokrian Zeini M; Kazemi K; Solaimanian S; Abdollahifar MA; Hedayatyanfard K; Dehpour AR
Int Immunopharmacol; 2021 Nov; 100():108160. PubMed ID: 34583123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
